Atreca has come down to rising channel support. There's also the 100 ema involved, which has many times acted as watershed support\resistance (YELLOW arrows). If this channel and moving average hold, BCEL could quickly go back to all-time highs for a 44% gain. If channel breaks to the downside, March lows are 40% away. I would absolutely wait for solid confirmation before taking any position on this stock today.
Full disclosure: long BCEL at 0.9% of total assets. Yet another post-IPO biotech stocks; very aggressive and volatile; HANDLE WITH CARE.
Full disclosure: long BCEL at 0.9% of total assets. Yet another post-IPO biotech stocks; very aggressive and volatile; HANDLE WITH CARE.